SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeymatm, a ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

A German multicentre study reveals strong patient demand for systemic therapy in atopic dermatitis and psoriasis. Learn more about treatment preferences and drivers.

In this MedPage Today video segment, Linda Stein Gold, MD, director of dermatology clinical research at the Henry Ford Health ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

By Dengyuemed International Business Department  November 28 — The National Medical Products Administration (NMPA) has approved the marketing of picankibart injection, an innovative IL-23p19–targeting ...

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring ...

People taking methotrexate for a variety of conditions have been warned by the NHS that a number of symptoms and side effects ...

In patients with plaque psoriasis, family history and palmoplantar involvement were among the predictors of early super response to bimekizumab.